| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 78,000 | 49,573 | 18,132 | 60,228 |
| Intangible asset impairment charges | NaN | 0 | 22,784 | 0 |
| Depreciation and amortization | 43,191 | 49,227 | 54,073 | 120,272 |
| Unrealized foreign currency loss (gain) | -8,215 | -1,153 | -3,207 | 11,813 |
| Amortization of debt issuance costs and discount | 3,890 | 3,715 | 5,030 | 13,686 |
| Reclassification of cash flow hedge | -2,878 | -2,942 | -4,163 | 5,876 |
| Change in fair value of contingent consideration | NaN | 0 | NaN | NaN |
| Loss on refinancing | -3,510 | 0 | -31,365 | NaN |
| Stock-based compensation | 8,816 | 8,202 | 8,219 | 15,532 |
| Inventory provision | 13,353 | 26,636 | 20,894 | 38,432 |
| Other operating charges and credits, net | -1,486 | -1,157 | -1,321 | -2,254 |
| Trade accounts receivable, net | -44,013 | 10,338 | 77,613 | 32,615 |
| Inventories | 54,959 | 20,180 | 30,807 | 36,039 |
| Prepaid expenses, other current assets and other assets | 13,400 | -1,010 | 10,158 | 10,015 |
| Related party receivables | 56 | -817 | -278 | 1,108 |
| Accounts payable, accrued expenses and other liabilities | -124,578 | 18,577 | 69,748 | -67,004 |
| Related party payables | -41,102 | -2,176 | -2,186 | 5,293 |
| Net cash (used in) provided by operating activities | -26,743 | 130,315 | 118,450 | 91,227 |
| Purchases of property, plant and equipment | 8,175 | 21,773 | 12,298 | 35,992 |
| Acquisition of intangible assets | 7,850 | 3,000 | 7,414 | 5,100 |
| Deposits for future acquisition of property, plant and equipment | 5,685 | 21,396 | 2,752 | 4,632 |
| Proceeds from sale of property, plant, equipment and other | NaN | 2,094 | NaN | NaN |
| Proceeds from sale of subsidiary | NaN | 0 | 0 | 0 |
| Proceeds from sale of property, plant and equipment | -1,379 | NaN | 0 | 1,379 |
| Net cash used in investing activities | -21,710 | -45,454 | -22,464 | -44,345 |
| Proceeds from issuance of debt | NaN | NaN | 2,694,750 | NaN |
| Payments of principal on debt, revolving credit facilities, financing leases and other | 140,842 | -5,616,892 | 2,554,308 | 251,076 |
| Proceeds from issuance of debt | 134,673 | 2,694,750 | NaN | NaN |
| Tax and other distributions to non-controlling interests | NaN | 43,848 | NaN | NaN |
| Payments of deferred financing, refinancing costs and debt extinguishment costs | NaN | 74,973 | NaN | NaN |
| Payments of deferred financing and refinancing costs | -72,991 | NaN | 73,228 | 1,745 |
| Payment of principal on notes payable - related party | NaN | 0 | 0 | 0 |
| Borrowings on revolving credit facilities | 0 | 0 | 0 | 218,000 |
| Proceeds from exercise of stock options | 38 | 553 | 653 | 754 |
| Employee payroll tax withholding on restricted stock unit vesting | 44,305 | 321 | 129 | 21,828 |
| Tax and other distributions to non-controlling interests | -31,678 | NaN | 13,867 | 24,958 |
| Proceeds from alliance party | 510 | 795 | 5,572 | NaN |
| Net cash used in financing activities | -59,055 | -10,120 | 59,443 | -80,853 |
| Effect of foreign exchange rate on cash | -1,023 | -209 | -694 | -777 |
| Net decrease in cash, cash equivalents, and restricted cash | -108,531 | 74,532 | 154,735 | -34,748 |
| Cash, cash equivalents, and restricted cash - beginning of period | 312,939 | 238,407 | 118,420 | NaN |
| Cash, cash equivalents, and restricted cash - end of period | 204,408 | 312,939 | 238,407 | NaN |
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)